Stem Cell Hospitals
Korean stem cell hospitals and centres: service menus, programme details and price ranges.
Profiles in this category
7Full provider and organisation profiles — services, pricing, medical team and outcomes.
Cell therapy manufacturerGMP · 4-drug pipelineEHL Bio Hospital: Korea's adult stem cell centre with its own research institute and GMP labs
EHL Bio Hospital (㈜이에이치엘바이오) is a Korean hospital specialising in adult stem cell therapy, founded in 2012. What sets it apart from ordinary stem cell clinics is that the hospital runs its own research institute in Uiwang, Gyeonggi-do and its own international-standard laboratories: two in-house GMP plants culturing more than 6,000 lots a year in CLASS 100 clean rooms, inspected by Korea's MFDS and holding a CPC licence from Japan's Ministry of Health, Labour and Welfare. Patient care centres on the EHL Cell Center at 136 Apgujeong-ro in Gangnam, Seoul. Core technology is autologous adipose-derived stem cells, behind a four-drug pipeline: ADSTEM for atopic dermatitis (Phase 3 IND filed in 2024), KDSTEM for chronic kidney disease (Phase 1 from 2023), RASTEM for rheumatoid arthritis (preparing Phase 1) and PDSTEM for Parkinson's disease (preclinical). It also produces EHL-STEM conditioned media with an internationally registered INCI name, works on NK, T, dendritic and iNKT immune cells and exosomes, and publishes 11 patent filings, alongside a network of roughly 100 partner hospitals in Korea and 50 overseas.
View profile
HospitalSVF · HuriCell®Cheongdam The Cell Stem Cell Hospital
Cheongdam The Cell (Cheongdam Stem Cell) is an autologous adipose stem-cell hospital in Busan, South Korea. It isolates SVF from the patient's own fat with HuriCell®, Hurim BioCell's closed automated system, and counts every batch on a SOL COUNT analyser. Packages start at KRW 4,000,000, with the 70–100 million-cell body + face programme at KRW 15,000,000 (regular KRW 20,000,000). Treatment is same-day.
View profile
Cell therapy centreCheongdam Cell Clinic
Cheongdam Cell Clinic (청담셀의원) is a stem cell and anti-ageing clinic on the 15th floor of SB Tower on Dosan-daero in Gangnam, Seoul. Its stated approach avoids cell cultivation: bone marrow is harvested, highly concentrated cells are isolated and reinjected, all within a single half-day. Five goal-based programmes are offered — 淸Cell for whole-body rejuvenation, 性Cell for sexual function, 美Cell for skin, 毛Cell for hair and 活Cell for chronic pain — led by Dr. Jo Chan Ho, an attending professor at Hanyang University and a director of the Korean Association of Stem Cell Therapy.
View profile
HospitalBong Bong Plastic Surgery & Wellness Clinic
Bong Bong (봉봉성형외과) is a plastic surgery hospital and wellness clinic in Gangnam, Seoul that extended from surgery into anti-ageing through its Basic Cell programme. It runs its own cell laboratory, uses a blood-based cell kit so treatment finishes the same day, delivers around 100 million cells per session, cites more than 2,000 clinical cases, and surrounds the therapy with six supporting programmes including hyperbaric oxygen, whole-body lymphatic care and IV nutrient therapy.
View profile
HospitalSVFBanobagi Plastic Surgery — SVF stem cell therapy
Banobagi Plastic Surgery (바노바기성형외과) in Gangnam, Seoul, offers SVF therapy — stromal vascular fraction. The patient's own blood, fat and bone marrow are processed into a five-part cell preparation: SVF cells, growth factors, SDF-1α, white blood cells and platelets. It is then returned to the body for skin repair, anti-ageing, immune support and scar treatment. The published protocol runs in four steps, with cells prepared inside the hospital's own one-stop sterile cabinet. Banobagi reports a survival rate of 96.7 ± 2.32% for blood-derived SVF and 90.73 ± 2.35% for bone-marrow-derived SVF.
View profile
ClinicLienjang Plastic Surgery
Lienjang (리엔장성형외과) is a plastic surgery hospital in Gangnam, Seoul, on floors 14–18 of 343 Gangnam Tower by exit 10 of Gangnam Station, with a dedicated Thai-language site and staff. Its stem cell menu has two programmes: facial stem cell injection and an intravenous stem cell drip. Both use non-cultured adult stem cells isolated from the patient's own blood, so the draw and reinjection happen the same day. A specialist anaesthesiologist is on staff and the clinic runs a signature aftercare programme called Inner Beauty.
View profile
HospitalWonjin Plastic Surgery
Wonjin (원진성형외과) is a plastic surgery hospital in Gangnam, Seoul, with a dedicated Thai-language site. Its anti-ageing menu includes a stem cell procedure using adult stem cells from the patient's own body: about 1–2 hours, no suture removal, no hospitalisation, numbing cream with sedation, and one day in Korea recommended. The harvested cells are applied three ways — stem cell fat grafting, facial skin rejuvenation and SmartPrep2 hair growth.
View profile
Cell therapy manufacturer hub
EHL Bio
The Korean stem cell R&D and manufacturing company behind cell therapy at roughly 100 partner hospitals — read its drug pipeline, GMP plants, licences and patents.
Open the full EHL Bio profile- Four stem cell drugs in the pipelineADSTEM · KDSTEM · RASTEM · PDSTEM
- GMP plants and licencesCLASS 100 · MFDS · Japan CPC
- Nine target disease groupsArthritis · cirrhosis · COPD
- NK and iNKT immune cellsSix cell types under research
- EHL-STEM conditioned mediaVEGF · FGF · EGF
- Eleven patents and papersThe academic paper trail
The full stem cell library
45 knowledge articles built from EHL Bio's own data — filter by topic or disease group.
EHL Bio: the Korean stem cell hospital with its own research company and GMP lab
EHL Bio is a Korean stem cell medical group that combines three things: a treating hospital, a bio research institute founded in 2012, and its own international-standard GMP laboratory able to culture over 6,000 cell lots per year. Its edge is proprietary technology for isolating and expanding a patient's own adipose-derived stem cells, plus a clinical pipeline of cell drugs including ADSTEM, KDSTEM, RASTEM and PDSTEM.
Inside EHL Bio's GMP lab: the standard that makes stem cells safe to infuse
GMP (Good Manufacturing Practice) is the regulator-defined manufacturing standard that keeps every production lot consistent. EHL Bio's first GMP centre was completed in 2015, inspected by Korea's MFDS in 2016, and a second centre opened in 2019, giving a combined 6,000 lots per year. Inside are particle-, temperature- and humidity-controlled cleanrooms, with all cell handling done in biological safety cabinets (BSC).
What are adipose-derived stem cells, and why does Korea use them?
Adipose-derived stem cells are mesenchymal stem cells (MSCs) isolated from a patient's own fat. They self-renew and can differentiate into bone, cartilage, muscle and neural lineages — but their bigger clinical value is immunomodulation and anti-inflammatory signalling, the main mechanism behind their use in chronic disease. Korea favours fat as the source because harvesting is simple, cell yield per gram is high, and autologous cells avoid rejection issues.
ADSTEM inj.: EHL Bio's stem cell drug for atopic dermatitis
ADSTEM inj. is EHL Bio's cell drug using the patient's own adipose-derived mesenchymal stem cells, given as two intravenous infusions, targeting moderate-to-severe subacute and chronic atopic dermatitis. Phase 1 finished in 2017 and the product was approved into phase 2, run at Chung-Ang University Hospital and five other sites.
KDSTEM inj.: urine-derived stem cells and Klotho for chronic kidney disease
KDSTEM inj. is EHL Bio's cell therapy candidate using the patient's own urine-derived mesenchymal stem cells, given as repeat intravenous infusions for chronic kidney disease. Its scientific hook is that these cells express Klotho, an anti-ageing protein with antioxidant, anti-senescence, angiogenic and metabolic-regulating roles. It sits in preclinical and early clinical development.
RASTEM inj.: stem cells for moderate-to-severe rheumatoid arthritis
RASTEM inj. is EHL Bio's autologous adipose MSC therapy, given as repeat intravenous infusions for moderate-to-severe rheumatoid arthritis. Preclinical work is complete and phase 1 preparation is under way. The concept is to use MSC immunomodulation to reduce autoimmune joint destruction.
PDSTEM inj.: EHL Bio's stem cell research for Parkinson's disease
PDSTEM inj. is EHL Bio's cell therapy candidate for Parkinson's disease, using the patient's own adipose MSCs by repeat intravenous infusion. It is currently in non-clinical study. The rationale is neuroprotection and reduced neuroinflammation rather than direct transplantation of dopaminergic cells as in embryonic stem cell research.
KEYCELL-IM inj.: EHL Bio's multi-immune-cell cancer therapy
KEYCELL-IM inj. is EHL Bio's immune cell therapy: NK, T, dendritic and iNKT cells are separated from the patient's own blood, each activated and expanded with proprietary culture technology, cryopreserved, then expanded for infusion. Its selling point is that a single apheresis collection yields roughly 30 times more cells than a standard blood draw, enough for 6-12 doses.
Stem cell exosomes: EHL Bio's research into neuropathic pain
Exosomes are nanovesicles every cell releases to signal to others, carrying proteins, lipids and small genetic material. EHL Bio is developing exosomes from adipose mesenchymal stem cells, with neuropathic pain as the lead indication, currently in animal studies supporting patent filings. Additional targets under study include cartilage regeneration, wound healing, diabetes, retinopathy and brain disorders.
EHL-Stem conditioned media: the real data on brightening and wrinkles
Stem cell conditioned media is the fluid produced while culturing stem cells, containing growth factors, cytokines, fibronectin and collagen. EHL Bio's EHL-Stem is INCI-registered as Human Adipose Stromal Cell Conditioned Media. Independent laboratory testing (Dermapro, January 2016) reported a 49% reduction in melanin production, 45% inhibition of tyrosinase and roughly a 9-fold increase in intracellular collagen synthesis.
Stem cells and Alzheimer's: the evidence EHL Bio cites
Alzheimer's damages the memory-controlling hippocampus and language cortex, with amyloid plaque a central driver. No drug fully dissolves plaque today, but stem cells have been reported to reduce amyloid in animal models. The work EHL Bio cites gave 13 stem cell doses to Tg2576 mice and, on the Morris water maze, found cognitive and physical function improved by 23.4% with a 31.3% increase in lifespan.
Stem cells for knee osteoarthritis: how far can an injection go?
Osteoarthritis is wear of the joint cartilage leading to inflammation, pain and restricted movement. The cell approach EHL Bio describes is harvesting the patient's own fat, expanding stem cells in the lab, then injecting selected high-quality cells into the affected joint to stimulate cartilage regeneration and reduce inflammation without joint replacement surgery. Results, though, depend heavily on how advanced the degeneration is.
Stem cells and diabetes: what EHL Bio's HbA1c numbers actually mean
EHL Bio publishes a case example where glucose fell from 300 to 120 mg/dL and HbA1c (NGSP) from 10.8% to 6.3% after stem cell treatment. The numbers are striking but they are single-case data, not a randomised controlled trial. The scientific rationale is that MSCs reduce chronic inflammation and insulin resistance, rather than fully regenerating beta cells.
Diabetic foot ulcers: how stem cells aim to save the limb
Diabetic foot ulcers are notoriously hard to heal, prone to spreading infection and sepsis, and in severe cases lead to toe or ankle amputation. EHL Bio reports using stem cells to help ulcers close and preserve foot function, showing wound progression before treatment and after the 1st, 2nd and 5th doses. The proposed mechanism is new capillary formation plus reduced chronic inflammation in the wound bed.
Stem cells and liver cirrhosis: hepatic artery delivery for liver repair
Cirrhosis replaces functioning liver tissue with fibrosis. The approach EHL Bio describes uses the patient's own multipotent stem cells injected directly into the hepatic artery so they can support regeneration of damaged liver tissue, with reported reductions in ascites volume and improved liver function. Using autologous cells also lowers immune rejection risk.
Stem cells, myocardial infarction and new blood vessel growth
A myocardial infarction occurs when a coronary artery blocks and heart muscle loses blood supply. The cell approach EHL Bio describes uses adult stem cells to stimulate vascular regeneration around the blockage, improving perfusion. This field began after Asahara's 1997 discovery of endothelial progenitor cells and clinical trials have expanded since, but it is not standard care in place of revascularisation.
Stem cells for chronic lung disease: hope, limits and what to ask
Chronic lung diseases such as emphysema and pulmonary fibrosis permanently damage alveoli and cut gas exchange. EHL Bio lists lung disease among conditions where stem cells hold potential, since MSCs are anti-inflammatory and anti-fibrotic. Human data, however, remain limited to small studies, so core treatment is still smoking cessation, inhaled bronchodilators, pulmonary rehabilitation and oxygen therapy where indicated.
Autoimmune disease and stem cells: the Th1/Th2 balance principle
There are over 100 autoimmune diseases, arising when the Th1/Th2 T-cell balance breaks and immunity attacks the body's own tissue. EHL Bio explains that stem cells help restore Th1/Th2 equilibrium, giving them potential in this disease group, and that they normalise both under- and over-active immunity. That is why cell therapy is being trialled across conditions from atopic dermatitis to rheumatoid arthritis.
Stem cells and erectile dysfunction: what the Urology journal data show
Most erectile dysfunction is vascular in origin: when penile vessels lose elasticity, blood escapes and erection cannot be sustained. The approach EHL Bio cites injects the patient's own abdominal fat-derived mesenchymal stem cells into the corpus cavernosum. The referenced study (Urology 2018;121:203.e6-203.e13) reported that six months after a single injection, participants' IIEF scores rose from about 6 to about 12 — moving from severe to mild-moderate dysfunction.
EHL Bio's patents and research: how to read them properly
EHL Bio publishes its patent and research list to demonstrate technical capability, spanning a fat harvesting/SVF separation kit, 15-PGDH inhibitor applications for atopic dermatitis and rheumatoid arthritis, and a three-dimensional low-oxygen culture method for producing conditioned media. The key distinction for readers: a patent protects an invention; it does not mean the product's efficacy is proven or that it is approved for treatment.
EHL Bio's history: from a 2012 research institute to a stem cell drug developer
EHL Bio began with a bio research institute founded in 2012, then built its own GMP cell-manufacturing centre, earned a Japanese CPC licence, grew a network of roughly 100 partner hospitals in Korea and 50 abroad, and pushed several cell drugs into clinical trials.
How EHL Bio tests cell quality: sterility, viability and purity
Before a lot is released, a GMP lab must test at least four things: sterility, mycoplasma, endotoxin, and the cells themselves — viability, cell count and the surface markers confirming they really are MSCs. These certificates are documents a patient is entitled to ask for.
A Thai patient's guide to stem cell treatment at EHL Bio in Korea
For Thai patients, treatment at EHL Bio usually means two trips: the first for assessment and fat harvesting, then roughly 4-6 weeks of culture, then a second trip for the infusions. Recent blood work and imaging must be reviewed by the medical team before any booking.
ADSTEM inj. in clinical trials: how to read the phase 1 and 2 results
ADSTEM inj. is EHL Bio's adipose stem cell drug for severe atopic dermatitis. Phase 1 focuses on safety and tolerated dose; phase 2 starts measuring efficacy such as eczema severity scores and itch. A phase 2 signal is not the same as approval for general use.
What urine-derived stem cells are, and why KDSTEM uses them for kidney disease
Urine-derived MSCs are cells shed from the urinary tract lining that can be expanded in culture. They are collected without surgery or a tissue biopsy and originate close to the renal system. EHL Bio's KDSTEM Inj. uses them for chronic renal failure, with a mechanism linked to the Klotho protein.
RASTEM vs biologic drugs in rheumatoid arthritis: what is different
Biologics in rheumatoid arthritis block a specific inflammatory signal such as TNF-alpha or IL-6. RASTEM, a cell drug in EHL Bio's pipeline, instead aims to modulate immune balance through the factors the cells secrete. The two are not interchangeable, and both belong under a rheumatologist's care.
PDSTEM and the outlook for cell therapy in neurodegenerative disease
PDSTEM is EHL Bio's pipeline cell drug aimed at Parkinson's disease. Neurodegeneration is hard because dead neurons do not regrow and therapies must cross the blood-brain barrier, so cell approaches focus on calming neuroinflammation and protecting surviving neurons rather than replacing lost ones.
Cell banking and cryopreservation: keeping stem cells usable for years
Long-term stem cell storage uses liquid nitrogen at about -196C together with a cryoprotectant such as DMSO and a controlled-rate freeze. The step that most affects final quality is thawing, which must be fast and followed by correct removal of the cryoprotectant.
SVF versus cultured stem cells: what is the real difference
SVF (stromal vascular fraction) is a mixed cell population separated from fat within a single day, containing only a modest share of stem cells. Cultured therapy instead selects and expands MSCs in a lab over 4-6 weeks, giving far higher cell numbers and fuller quality testing, at the cost of time and money.
Passage number and stem cell potency: what patients should know
Each time cells are moved to fresh culture vessels counts as one passage. The higher the passage, the closer cells drift to senescence: slower division and weaker secretion of therapeutic factors. Good labs therefore cap passage number and test potency per lot rather than counting cells alone.
Stem cells and recovery after stroke
After a stroke the brain's capacity to rewire peaks in the first 3-6 months, and structured rehabilitation remains the best-evidenced treatment. Cell therapy sits at the research stage, with the hope of reducing inflammation and encouraging new blood vessel growth around the damaged area.
Stem cells for spinal cord injury: hope versus evidence
Spinal cord injury produces a glial scar that physically and chemically blocks nerve regrowth. Cell research therefore aims to lower inflammation, limit fibrosis and create a more permissive environment for connections — not to splice severed nerves. It remains investigational and case-by-case.
Diabetic peripheral neuropathy: what stem cells may and may not do
Diabetic peripheral neuropathy comes from chronic high glucose damaging both nerves and the microvessels that feed them. The cell therapy rationale is to promote new capillaries and reduce inflammation, which may ease numbness and burning in some patients — but glucose control remains the decisive factor.
Fatty liver and stem cells: what can be done before cirrhosis
Non-alcoholic fatty liver disease can progress to steatohepatitis, fibrosis and eventually cirrhosis. Losing 7-10% of body weight remains the best-evidenced intervention; stem cell work targets inflammation and fibrosis in liver tissue and is not a substitute for lifestyle change.
Heart failure: stem cells and cardiac muscle recovery
Heart failure means the heart cannot pump enough for the body's needs, commonly graded by ejection fraction. Cell research targets myocardial fibrosis and new capillary growth; reported gains tend to be in six-minute walk distance and quality of life rather than large EF jumps.
Type 1 vs type 2 diabetes: why the stem cell approach differs
Type 1 diabetes is autoimmune destruction of pancreatic beta cells; type 2 combines insulin resistance with declining beta-cell function. The cell therapy goals differ accordingly: immune modulation and protection of residual beta cells in type 1, versus lowering inflammation and improving insulin sensitivity in type 2.
Insulin resistance and metabolic syndrome: where cell therapy fits
Metabolic syndrome is a cluster — excess waist circumference, high blood pressure, high triglycerides, low HDL and elevated glucose — with insulin resistance at its centre. The MSC rationale is to reduce the chronic inflammation linking them, always alongside weight loss and exercise.
Chronic wounds that will not close: how exosomes and stem cell factors help
A chronic wound is one that has not healed in 4-6 weeks, usually because of poor perfusion, infection or stalled inflammation. Exosomes and stem cell secreted factors carry growth signals that encourage capillary and collagen formation — but only alongside standard wound care.
Lupus (SLE) and cell therapy: retraining an immune system that attacks itself
Lupus is an autoimmune disease that can affect skin, joints, kidneys and blood. Mainstay therapy is immunomodulators and steroids scaled to severity. MSC research focuses on patients refractory to standard treatment, aiming to expand regulatory immune cells and calm inflammation.
Psoriasis: when the skin mirrors an immune problem
Psoriasis arises when immune signalling drives skin cells to divide far too fast, producing thick scaly plaques. A share of patients also develop arthritis, and metabolic risk runs higher than average. The cell therapy idea is systemic immune rebalancing rather than treating skin alone.
Crohn's disease and IBD: the stem cell angle
Crohn's disease and ulcerative colitis involve immune-driven gut inflammation interacting with the microbiome. The best-supported MSC use is local injection for perianal fistulas in Crohn's — a complication that responds poorly to standard treatment.
Men's vitality stem cell programmes: separating fact from marketing
Clinic 'male vitality' packages often bundle stem cells, IV vitamins and hormones. The first step is finding the real cause of the fatigue — low testosterone, sleep apnoea, anaemia, thyroid disease or diabetes — because each has a specific treatment that works better.
Male hair loss: exosomes and stem cells versus standard treatment
Male pattern hair loss is driven by DHT progressively miniaturising follicles. The best-evidenced treatments are minoxidil and 5-alpha reductase inhibitors. Exosomes and stem cell factors are adjuncts that may improve density in some patients but do not stop the hormonal mechanism.
Male infertility: where stem cell research actually stands
Roughly half of male infertility has a correctable cause: varicocele, infection, hormonal disorders, heat exposure and habits such as smoking. Stem cell research here is early stage and not standard care, so a proper cause workup always comes first.
Age-related low testosterone: a safe way to approach it
Testosterone declines slowly with age, roughly 1% per year after 30. Symptoms such as fatigue, lower libido and muscle loss are non-specific, so at least two morning blood tests are needed before concluding anything. Hormone therapy has both benefits and risks that must be weighed with a physician.
Related reading
- Stem cellEHL Bio Hospital: Korea's adult stem cell centre with its own research institute and GMP labsEHL Bio Hospital (㈜이에이치엘바이오) is a Korean hospital specialising in adult stem cell therapy, founded in 2012. What sets it apart from ordinary stem cell clinics is that the hospital runs its own research institute in Uiwang, Gyeonggi-do and its own international-standard laboratories: two in-house GMP plants culturing more than 6,000 lots a year in CLASS 100 clean rooms, inspected by Korea's MFDS and holding a CPC licence from Japan's Ministry of Health, Labour and Welfare. Patient care centres on the EHL Cell Center at 136 Apgujeong-ro in Gangnam, Seoul. Core technology is autologous adipose-derived stem cells, behind a four-drug pipeline: ADSTEM for atopic dermatitis (Phase 3 IND filed in 2024), KDSTEM for chronic kidney disease (Phase 1 from 2023), RASTEM for rheumatoid arthritis (preparing Phase 1) and PDSTEM for Parkinson's disease (preclinical). It also produces EHL-STEM conditioned media with an internationally registered INCI name, works on NK, T, dendritic and iNKT immune cells and exosomes, and publishes 11 patent filings, alongside a network of roughly 100 partner hospitals in Korea and 50 overseas.
- Stem cellEHL Bio: the Korean stem cell hospital with its own research company and GMP labEHL Bio is a Korean stem cell medical group that combines three things: a treating hospital, a bio research institute founded in 2012, and its own international-standard GMP laboratory able to culture over 6,000 cell lots per year. Its edge is proprietary technology for isolating and expanding a patient's own adipose-derived stem cells, plus a clinical pipeline of cell drugs including ADSTEM, KDSTEM, RASTEM and PDSTEM.
- TreatmentDisease treatment in South Korea: among Asia's most advanced medical careSouth Korea is one of Asia's most advanced centres for disease treatment, with cancer survival rates above the global average for several cancers and technologies such as proton beam therapy, da Vinci robotic surgery and MR-guided focused ultrasound in routine use at major Seoul hospitals. Costs run far below the United States, so international patient numbers grow every year, supported by full-service international desks with interpreters at tertiary hospitals like Asan, Samsung, Severance and Seoul National University Hospital.
- ResearchResearch: adipose stem cells for knee osteoarthritisMultiple clinical studies report that intra-articular adipose-derived stem cell injections reduce pain and improve function in mild to moderate knee osteoarthritis, though larger trials with long-term follow-up are still needed.
Knowledge articles in this category
Explainers, comparisons and guides for this category — not provider profiles.
Popular questions
See all questionsCan exosomes replace stem cells?
Not exactly — they deliver signals but no cells that adapt to the environment; treat them as different tools.
Stem cellChronic wounds that will not close: how exosomes and stem cell factors helpIs stem cell therapy necessary?
No — start with standard care and consider adjuncts only when a physician judges it appropriate.
Stem cellFatty liver and stem cells: what can be done before cirrhosisCan fatty liver reverse?
Early stages can reverse with real weight loss and diet change; once significant fibrosis exists, reversal is much harder.
Stem cellFatty liver and stem cells: what can be done before cirrhosisCan lost sensation return?
Partly, if nerves are not permanently damaged; established damage rarely reverses completely.
Stem cellDiabetic peripheral neuropathy: what stem cells may and may not doIs walking again possible?
It depends chiefly on lesion level and completeness. No method can guarantee it, and outcome promises should be treated with suspicion.
Stem cellStem cells for spinal cord injury: hope versus evidenceIs late administration still useful?
The later it is, the smaller the expected benefit as brain repair plateaus — though rehabilitation continues to help.
Stem cellStem cells and recovery after stroke
Popular questions on Korean surgery, skin clinics, travel, culture and daily life — each with a short, direct answer.
Related articles
- HeightDr. Donghoon Limb Lengthening Institute (DALRI)Dr. Donghoon Advanced Limb Lengthening & Reconstruction Institute (DALRI) in Seongnam, Gyeonggi-do specialises in stature lengthening, bowleg and knock-knee correction, leg length discrepancy and revision surgery, led by Dr. Lee Dong Hoon — the first surgeon in Asia to complete PRECICE nail lengthening.
- HeightHeight surgery reviews 2026: real before & after cases from DALRIReal height-surgery reviews from the Dr. Donghoon institute (DALRI) in South Korea show gains of roughly 5–6.5 cm per lengthened segment. Most cases lengthen the tibia with LON or PRECICE and are followed with radiographs from six months to over two years post-op. Every figure here comes from the hospital's own published captions, not an estimate.
- HeightHeight surgery cost in Korea 2026: full price breakdownHeight (limb-lengthening) surgery at Dr. Donghoon's institute (DALRI) in South Korea starts at KRW 52,800,000 (about THB 1.27M) for LON tibia lengthening and runs KRW 117,420,000–131,760,000 (about THB 2.8–3.2M) for the internal PRECICE nail. Prices cover surgery, anaesthesia, implants and 7 nights of ward stay, but exclude housing and living costs during recovery in Korea.
- SurgeryEpic Plastic SurgeryEpic Plastic Surgery is a Seoul hospital in Sinsa, Gangnam, focused on eye surgery, rhinoplasty, anti-aging lifting, men's surgery and breast surgery. Its signature promise is that the consulting surgeon performs the operation — no shadow doctors.
- SurgeryID HospitalID Hospital is one of Seoul's largest hospitals specialising in facial bone and jaw surgery. Located in Gangnam with 30+ board-certified surgeons, it is best known for V-line two-jaw surgery and 3D CT-based surgical planning.
- DevicesShurink UniverseShurink Universe is a Korean HIFU platform delivering focused ultrasound to the SMAS layer for non-surgical lifting. The newer generation fires faster with less discomfort, suiting mild to moderate laxity.